Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Aurinia Pharmaceuticals ( (AUPH) ) just unveiled an announcement.
Aurinia Pharmaceuticals announced its financial results for the quarter ending June 30, 2025, reporting a 22% increase in total revenue to $70 million compared to the same period in 2024. The company also revealed that its Board of Directors approved an additional $150 million for its share repurchase plan, indicating a strong financial position and commitment to enhancing shareholder value.
The most recent analyst rating on (AUPH) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Aurinia Pharmaceuticals stock, see the AUPH Stock Forecast page.
Spark’s Take on AUPH Stock
According to Spark, TipRanks’ AI Analyst, AUPH is a Outperform.
Aurinia Pharmaceuticals has a solid overall stock score, driven by strong financial performance and positive earnings call highlights. However, the high valuation and mixed technical signals, along with potential risks from patent litigation and market competition, moderate the score.
To see Spark’s full report on AUPH stock, click here.
More about Aurinia Pharmaceuticals
Aurinia Pharmaceuticals Inc. is a biopharmaceutical company based in Canada, primarily focused on developing and commercializing therapies for patients with serious diseases. Its key product, LUPKYNIS, is the first FDA-approved oral therapy for treating adult patients with active lupus nephritis.
Average Trading Volume: 1,539,616
Technical Sentiment Signal: Buy
Current Market Cap: $1.21B
Learn more about AUPH stock on TipRanks’ Stock Analysis page.